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RBM10, originally called S1-1, is a nuclear RNA-binding protein with domains characteristic of RNA
processing proteins. It has been reported that RBM10 constitutes spliceosome complexes and that
RBM5, a close homologue of RBM10, regulates alternative splicing of apoptosis-related genes, Fas
and cFLIP. In this study, we examined whether RBM10 has a regulatory function in splicing similar
to RBM5, and determined that it indeed regulates alternative splicing of Fas and Bcl-x genes. RBM10
promotes exon skipping of Fas pre-mRNA as well as selection of an internal 50-splice site in Bcl-x pre-
mRNA. We propose a consensus RBM10-binding sequence at 50-splice sites of target exons and a
mechanistic model of RBM10 action in the alternative splicing.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction [7], and a G-patch motif found in some eukaryotic RNA-processingRBM10, originally called S1-1, is an RNA-binding protein [1].
Loss of its function results in various deformities such as cleft
palate and malformation of the heart (TARP syndrome) [2,3] and
diseases such as lung adenocarcinoma [4].
S1-1/RBM10 exists in nuclear components called S1-1 nuclear
bodies and S1-1 granules. When transcription is globally halted,
S1-1 nuclear bodies dynamically enlarge with a concomitant dim-
inution of hundreds of S1-1 granules. The S1-1 granules localize on
perichromatin ﬁbrils, which are the sites of transcription and splic-
ing, and the new states resulting from these changes reversibly
return to the initial states upon recovery of transcriptional activity
[5]. Thus, S1-1 is likely associated with the gene expression
process.
RBM10 preferentially binds to G- and U-rich RNA sequences [1],
and contains the domains that suggest its involvement in RNA pro-
cessing [6]: two RNA-recognition motifs (RRMs) [1], a C4 Zn ﬁnger
that preferentially binds to 50-splice site-like single-stranded RNAsproteins [8]. RBM5, a close homologue of RBM10, has been shown
to regulate alternative splicing of pre-mRNAs of apoptosis-related
genes, FAS, c-FLIP [9], and caspase 2 [10]. To demonstrate its
splicing regulatory function by RNA interference (RNAi), it was
necessary to knock down not only RBM5 but also RBM10 and
RBM6 at the same time, thereby suggesting that RBM5 and
RBM10 have overlapping functions [9]. Furthermore, RBM10 has
been shown in splicing complexes [11] and in spliceosome A
[12,13] and B complexes [13,14], constituting a core protein of
these complexes [15]. These lines of evidence all support the
notion that RBM10 participates in alternative splicing. In this
study, we examined this long-standing assumption and veriﬁed
that RBM10 indeed regulates alternative splicing. We also discuss
functional differences between RBM5 and 10.
2. Materials and methods
2.1. Cells and cell culture
Human cell lines (HeLa cells derived from cervical carcinoma
and HLE cells from hepatoma) were cultured in Dulbecco’s Modi-
ﬁed Eagle’s Medium (Nissui) containing 100 lg/mL streptomycin,
100 IU/mL penicillin, and 5% fetal calf serum (Gibco BRL).
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cDNA of the human RBM10 larger isoform, with an EcoRV linker
immediately upstream to the 50-initiation codon and an XbaI linker
following the 30-stop codon, was prepared by PCR ampliﬁcation
using primers indicated in the Supplementary material. The cDNA
and vector pTRE-Tight (BD Sciences) were digested with EcoRV and
XbaI and ligated to obtain pRBM10/TRE-Tight. After propagation,
puriﬁcation, and sequence conﬁrmation, the plasmid was intro-
duced into HeLa Tet-On cells (BD Sciences Clontech) using Easy
Transgater (Apharmas). The culture of the transfected cells and
development of a stable cell line (HeLa RBM10 Tet-On h08) were
performed, as suggested by the supplier, in the presence of G418
and hygromycin for selection and maintenance.
2.3. Knockdown and overproduction of RBM10
HLE and HeLa cells were transfected with 10 nM speciﬁc human
RBM10-siRNA5 or with control AllStar siRNA using HiPerFect
transfection reagent (all from Qiagen) and incubated for 4 d.
RBM10 expression was induced in HeLa RBM10 Tet-On cells by
incubation with 2 lg/mL doxycycline (Dox) for 24 h.
2.4. Isolation of RNA and reverse transcription
Total RNA was isolated with Trizol (Invitrogen) as indicated by
the supplier. Reverse transcription of 1.5 lg of total RNA was
carried out at 37 C for 17 min using a PrimeScript RT reagent kit
(Takara) and mixed primers of oligo dT (0.25 lM) and random
oligonucleotides (0.5 lM).
2.5. PCR
PCR was carried out at 95 C for 15 s, followed by 27–30 cycles
of 95 C for 15 s, 58.5 C for 15 s, and 72 C for 20 s, and ﬁnally atc 
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Fig. 1. RBM10 regulates alternative splicing of Fas transcript. HLE and HeLa cells were tr
Dox for 24 h. (a) RBM10 was analysed by immunoblotting of total proteins on an 8.8% or 1
the relative abundance of RBM10 in each group is indicated at the bottom. C, control AllS
total RNAs, and analysed by PCR for changes in the alternative splicing of Fas pre-mRNA u
exon 6 skipping and (2) for inclusion, the reactions producing antiapoptotic and proapop
primers. (c) PCR products were analysed by PAGE (12.5% gels). The product sizes are in
adjusted to number of molecules, and changes in BI ratio, (1)/(2), are presented as a colum
experiments (Table 1a) is indicated. ⁄P < 0.05.72 C for 7 min using AmpliTaq Gold PCR Master Mix (Applied Bio-
systems) with template cDNA equivalent to 15 ng of total RNA and
a high concentration (0.75 mM each) of primers (Supplementary
material). The PCR conditions were semi-quantitative, and no more
than 2–5% of input primers were consumed. Each primer set for
caspase 2, 3, and 9 or Bcl-x simultaneously ampliﬁed two alterna-
tively spliced isoforms. For Fas or FLIP, two primer sets were used
to amplify respective isoforms, and reaction mixtures were com-
bined before gel electrophoresis. The PCR products, resolved on
12.5% polyacrylamide gels (e-PAGEL; Atto Corp.), were stained
with SYBR Green I (Lonza), and their band intensities (BIs) were
measured in arbitrary units under an LAS-3000 luminescent image
analyzer (Fujiﬁlm). BIs were compared after adjusting to number of
molecules. For example, in Fas splicing, the BI of exon 6-skipped
DNA (PCR product size: 85 bp) was compared with that of exon
6-included DNA (118 bp) after multiplication by 118/85.
2.6. Immunoblotting
Western blotting was performed as previously described [5],
where proteins (2.5 lg) were resolved on an 8.8% or 10% gel
(e-PARGEL; Atto) by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE).3. Results
3.1. RBM10 regulates alternative splicing of Fas transcript
Fas is a widely expressed cell surface receptor. The binding of
Fas to its ligand on an adjacent cell initiates a cascade leading to
cell death. The Fas pre-mRNA can be alternatively spliced to pro-
duce the membrane-bound, proapoptotic Fas receptor and a solu-
ble antiapoptotic isoform with exon 6 skipped [16,17]. RBM5
regulates this alternative splicing and increases exon 6 skipping. HLE HeLa HeLa Tet-on 
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depletion of RBM5, RBM6, and RBM10 was necessary, which
suggested that the corresponding proteins have overlapping
functions [9]. We examined this assumption about RBM10
function, and found that depletion of RBM10 alone was enough
to decrease exon 6 skipping in HeLa cells as well as HLE cells. When
approximately 95% of RBM10was silenced (Fig. 1a, Fig. S1a), exon 6
skipping was diminished by 68% in HLE cells and by 75% in HeLa
cells (Fig. 1c and d). Conversely, a 1.7-fold overexpression of
RBM10 in HeLa Tet-on cells (Fig. 1a, Fig. S1b) resulted in a 3.7-fold
increase in the skipping (Fig. 1c and d). The results were highly
reproducible (Table 1a) and indicate that RBM10 indeed regulates
splicing and promotes exon 6 skipping in Fas transcripts. The
similar results with two different cell lines, HeLa and HLE, suggest
that the observed RBM10 function is general rather than speciﬁc to
a particular cell type.
3.2. RBM10 in alternative splicing of other apoptosis-related genes
We further examined whether RBM10 participates in alterna-
tive splicing of other apoptosis-related genes that produce
isoforms with opposite functions.
3.3. c-FLIP
The FLIP gene produces isoforms c-FLIP(S) and c-FLIP(L). The
c-FLIP(S) isoform arises from exon 7 inclusion and is a strong
inhibitor of the Fas pathway, preventing proteolytic activation ofTable 1
RBM10 effects on alternative splicing of some apoptosis-related genes. Changes in the alte
primers used in PCR are indicated in Supplementary material. Band intensities (BIs) of amp
adjusted to number of molecules. (a) Fas. Values are average with S.E.M. of quadruplicate d
genes. Values are average of duplicate determinations with deviation. Bcl-x was analyzed
(a) Alternative splicing of Fas exon 6
Knockdown with siRNA
HLE HeLa
Skip inclusion BI ratio Skip inclu
(1)d (2)d (1)/(2)e S.E.M. (1) (2)
Controlb 53.3 46.5 1.15 0.123 32.3 67.7
SiRNA or Doxc 27.2 72.8 0.37 0.103 10.6 89.4
(0.32)f
(b) Alternative splicing of other apoptosis-related genes
Knockdown with siRNA
HLE
Genes Exona Skip inclusion BI ratio
(1)d (2)d (1)/(2)e
c-FLIP 7 (L)g (S)g
Controlb 10.4 89.6 ± 1.3
siRNA or Doxc 10.8 89.2 ± 2.0
Casp-2 9 2Lg 2Sg
Control 95.7 4.3 ± 0.1
siRNA or Dox 96.4 4.6 ± 1.0
Casp-3 6 3sg 3g
Control 22.5 77.5 ± 1.5
siRNA or Dox 25.4 74.7 ± 1.6
Casp-9 3–6 cassette 9bg 9ag
Control 98.4 1.6 ± 0.7
siRNA or Dox 98.5 1.5 ± 0.4
Bcl-x 2 Sg Lg
Control 72.2 27.8 ± 2.2 2.63
siRNA or Dox 69.3 30.7 ± 0.8 2.26
(0.86)f
a Exon: target exons in (b) that undergo alternative splicing.
b Control: cells were either transfected with control siRNA or incubated in the absenc
c siRNA or Dox: cells were either transfected with speciﬁc RBM10-siRNA or incubated
d Percentages of two alternative splicing events, calculated from BI values that were a
e (1)/(2) ratios.
f The (1)/(2) ratios of ‘siRNA or Dox’ were divided by those of corresponding ‘Control
g Name of isoform.procaspase 8, while the exon 7-skipped isoform, c-FLIP(L), is less
inhibitory or may act as an activator in the Fas pathway [9,18].
Here again, in contrast to the simultaneous depletions of RBM5,
6, and 10 [9], depletion of RBM10 alone decreased exon 7 skipping
in HeLa cells by approximately 2%. Conversely, overproduction of
RBM10 enhanced the skipping by 3% (Table 1b). However, these
changes were small and not observed in HLE cells. Furthermore,
as much as 89–92% of the splicing was the inclusion event
irrespective of the different levels of RBM10 (Table 1b). Hence,
we concluded RBM10 was not important for this reaction.
3.4. Caspase 2
Caspase 2 pre-mRNA produces proapoptotic caspase 2L and
antiapoptotic caspase 2S. The latter mRNA includes exon 9 that
harbors a premature termination codon, producing a short isoform
with no caspase activity [19,20]. RBM5 has been shown to enhance
exon 9 skipping in human embryonic kidney (HEK) cells and HeLa
nuclear extract to produce caspase 2L [10]. Accordingly, we exam-
ined RBM10 for similar activity. However, neither knockdown nor
overexpression of RBM10 produced any signiﬁcant effect on exon 9
skipping of caspase 2 pre-mRNA (Table 1b).
3.5. Caspase 3
Exon 6 of caspase 3 pre-mRNA undergoes alternative splicing.
Skipping this exon results in a truncated antiapoptotic isoform,
caspase 3s [21]. In the present study, signiﬁcant changes werernative splicing were analyzed by PCR followed by PAGE as in the Fig. 1 legend. The
liﬁed DNAs corresponding to exon skipping (1) and inclusion (2) were measured and
eterminations from two independent experiments (n = 4). (b) Other apoptosis-related
for selection of the internal (1) and external (2) 50-splice site.
Overprod. with Dox
HeLa Tet-On
sion BI ratio Skip inclusion BI ratio
(1)/(2) S.E.M. (1) (2) (1)/(2) S.E.M.
0.48 0.106 27.6 72.4 0.38 0.078
0.12 0.036 58.7 41.3 1.42 0.131
(0.25)f (3.74)f
Overprod. with Dox
HeLa HeLa Tet-On
Skip inclusion BI ratio Skip inclusion BI ratio
(1) (2) (1)/(2) (1) (2) (1)/(2)
(L) (S) (L) (S)
10.5 89.5 ± 1.0 8.2 91.9 ± 0.7
8.7 91.3 ± 1.0 11.2 88.8 ± 0.6
2L 2S 2L 2S
92.6 7.4 ± 0.2 95.5 4.5 ± 0.2
93.7 6.3 ± 0.1 96.0 4.0 ± 0.1
3s 3 3s 3
7.5 92.5 ± 0.8 23.4 76.7 ± 0.2
8.3 91.8 ± 1.2 24.9 75.2 ± 0.2
9b 9a 9b 9a
92.3 7.7 ± 0.5 95.6 4.5 ± 1.4
92.5 7.5 ± 0.1 95.7 4.3 ± 0.4
S L S L
66.3 33.7 ± 1.1 1.97 63.7 36.3 ± 1.6 1.75
58.8 41.5 ± 0.8 1.41 72.5 27.5 ± 1.3 2.64
(0.72)f (1.51)f
e of Dox.
with Dox.
djusted to number of molecules. The sum of the values (1) and (2) is 100%.
’. The values obtained for Fas and Bcl-x are indicated in parentheses.
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duction of RBM10 (Table 1b).
4. Effects of RBM10 on apoptosis-related genes undergoing
other types of alternative splicing
4.1. Caspase 9
Two splice isoforms are derived from the caspase 9 gene,
proapoptotic caspase 9a and truncated antiapoptotic 9b (also
called caspase-9S), by inclusion or exclusion of a cassette of exons
3–6 [22]. No effect was observed by knockdown or overproduction
of RBM10 in this alternative splicing (Table 1b).
4.2. Bcl-x
The Bcl-x pre-mRNA is alternatively spliced at two competing
50-splice sites present in exon 2, which is the ﬁrst coding exon of
the Bcl-x transcript, producing shorter proapoptotic Bcl-x(S) and
longer antiapoptotic Bcl-x(L) (Fig. 2). Expression of the Bcl-x(S) iso-
form, which antagonizes Bcl-x(L) as well as Bcl-2, is sufﬁcient to in-
duce apoptotic cell death in a wide range of cell types [23,24].
RBM10 knockdown reduced Bcl-x(S) production in both HLE cells
and HeLa cells, while Bcl-x(S) was conversely increased by
overproduction of RBM10 in HeLa Tet-on cells, although the effects
were not large (Table 1b, Fig. 2b and c).
5. Discussion
In the present study, we proved the long-standing assumption
that RBM10 regulates alternative splicing; RBM10 signiﬁcantlyc
b
a
(2)
(1)
Rev
exon 2
Bcl-x(L)
Bcl-x(S)
exon 3
Primers:   Fw
B
cl
-x
 (S
) /
 B
cl
-
x
 (L
),  
 
(1)
/(2
)
C CSi Si D(–)D(+)
0
1.0
3.0
2.0
HLE HeLa HeLa Tet-on
625
435
(2)
(1)
(bp)
D(–)D(+)C Si C Si
HLE HeLa HeLa Tet-on
Fig. 2. RBM10 regulates 50-splice site selection in Bcl-x transcripts. (a) Bcl-x
produces proapoptotic Bcl-x(S) (1) and anti-apoptotic Bcl-x(L) (2) due to the
presence of two competing 50-splice sites in exon 2. The primers, Fw and Rev,
simultaneously amplify two splicing events. (b) Bcl-x alternative splicing was
examined as described in the legend to Fig. 1: subsequent to PCR, ampliﬁed DNAs
were analyzed by PAGE. The product sizes are indicated on the right. (c) BIs of Bcl-
x(S) (1) and Bcl-x(L) (2) in (b) were adjusted to number of molecules, and the BI
ratios, (1)/(2), are presented as a column graph. Deviation from an average of
duplicate determination is indicated.enhanced the exon 6 skipping of Fas gene and, to a lesser extent,
the selection of an alternative 50-splice site in exon 2 of the Bcl-x
gene.
RBM5 and RBM10 are composed of more than 800 amino acid
(aa) residues with 50% sequence identity. The present study
showed that, in contrast to the depletion of RMB5 in HeLa cells
[9], the depletion of RBM10 alone was sufﬁcient to decrease
exon 6 skipping of Fas pre-mRNA. Conversely, while RBM 5 en-
hances exon 9 skipping of caspase 2 pre-mRNA [10], RBM10
had no such activity. In fact, the preference of RBM10 and 5
for RNA is different: RBM10 binds to RNA homopolymers prefer-
entially in the order poly G = poly U > poly C poly A [1], while
RBM5 does so in the order poly G > poly C > poly AP poly U
[25]. Accordingly, we expect that the activities and substrate
speciﬁcities of RBM10 and RBM5 in alternative splicing are con-
siderably different. Elucidation of the target genes of RBM10 and
RBM5 will help understand their roles and signiﬁcance in cellu-
lar function as well as in various diseases that arise from loss of
their functions.
RBM10 interacts with several proteins, including the branch-
point-binding protein SF1, another spliceosome A complex protein
SF4, as well as the U2-related proteins SR140 and DEAH helicase
hPRP43 [15]. Interestingly, SPF45, a regulator of alternative splic-
ing [26], interacts with the same set of proteins [15]. The common
protein interaction networks support the present notion that
RBM10 is a regulator of alternative splicing.
From our results and previous reports, a possible mechanistic
model of RBM10 action can be envisaged (Fig. 3). RBM10 has a
RanBP2-type Zn ﬁnger at aa 212–243 (aa135–166 in 852 residue
isoform), which has been shown to bind with high afﬁnity to
single-stranded 50 splice site-like RNA with a sequence aGGUaa
(lower case letters are less conserved) [7,27]. In addition, as
mentioned above, RBM10 preferentially binds to G and U polyribo-
nucleotides and little to poly(A), suggesting that RBM10 prefers
G- and U-rich sequences [1]. Intriguingly, the 50-splice-site region
of exon 6 in Fas pre-mRNA has a sequence uuguuuggG|GUa-
aguucuu, where the 50-splice site gG|GUaag is heavily surrounded
by U and G bases (vertical line indicates the exon–intron bound-
ary) (Fig. 3a). Therefore, RBM10 is likely to bind to this 50-splice
site, consequently blocking the site for splicing and bringing about
exon 6 skipping. This model is supported by the results of Bcl-x
pre-mRNA alternative splicing, where RBM10 led to selection of
internal 50-splice site of exon 2 (Fig. 3b). The 50-splice site of exon
2 has a sequence GG|GUAAG, which is the same as that of exon 6 in
Fas pre-mRNA shown above. Hence, RBM10 also likely binds to and
blocks this 50-splice site of exon 2, thereby allowing the selection of
the internal 50-splice site at 189 nucleotides upstream. The rather
week RBM10 effect in this reaction (compare Fig. 2 and Fig. 1)
may be due to low G/U abundance around the 50-splice site. Based
on the information presented here, we expect that the heptamer
GGGUAAG is an RBM10 consensus binding sequence and is found
at 50-splice sites of target exons, and that the RBM10 action is
promoted by a sequence(s) composed of about 6–8 or possibly
more G and/or U bases in the vicinity of target 50-splice sites.
Additionally, some other mechanistic component(s) may be
required to collaborate in the splicing regulation.
Wang et al. very recently have reported [28] that RBM10 func-
tions primarily in regulating exon-skipping, and the conclusion is
essentially the same as the present study. By photoactivatable-
ribonucleoside-enhanced crosslinking and immunoprecipitation,
they showed that as many as 6396 genes of HEK cells are targets
of RBM10, and their RBM10-binding sites are enriched in exons
and in the vicinity of both 50- and 30-splice sites. Among the 21
exon-splicing changes validated by RNA-Seq and qPCR, 74% of
them were skipping events. Wang et al. postulated a mechanistic
model, in which RBM10 molecules promote exon skipping by
ab
Fas
Bcl-x
uuugaacaG|GUagugaauga
ggcggcugG|GUaagaaccaag
exon 2 exon 3
5’ splice site of exon 2
Internal 5’ splice site of exon 2
exon 6 exon 7exon 5
caaccuacAG|Gauccagaucu
3’ splice site of exon 6
5’ splice site of exon 6
aagaggaaG|GUaauuauuuu uuguuuggG|GUaaguucuug
guucuuucAG|Ugaagagaaag
Fig. 3. Mechanistic model of RBM10-mediated regulation: putative consensus RBM10-binding sequence. RBM10 is proposed to recognize GGGUAAG at the 50-splice sites of
exon 6 in Fas pre-mRNA (a) and of exon 2 in Bcl-x pre-mRNA (b). The RBM10 binding may inhibit splicing at these sites, and promote skipping of exon 6 in Fas pre-mRNA or
the selection of an upstream 50-splice site in exon 2 in Bcl-x pre-mRNA. Red indicates the 50-splice site sequences. G|GU is the conserved 50-splice site trinucleotide. Vertical
lines indicate exon–intron boundary.
946 A. Inoue et al. / FEBS Letters 588 (2014) 942–947binding in the vicinity of 4 splice sites of upstream and
downstream introns [28]. They veriﬁed the RBM10 function with
reporter minigenes, and interestingly showed that exon skipping
was brought about by a single RBM10 molecule placed near the
50-splice site of a target exon. This RBM10 arrangement was
achieved with the aid of a PUF-3 domain fused to RBM10 and a
PUF domain recognition sequence located in the intronic region
of the reporter close to the 50-splice site. Notably, this system
and our present model are conformationally very similar at target
50-splice sites, although we suggest that RBM10 binds directly to
these sites. Furthermore, we demonstrated that RBM10 regulates
alternative splicing of Fas and Bcl-x, and that RBM10 not only leads
to exon-skipping, as shown with Fas, but also to 50-splice site
selection, as shown with Bcl-x.
The exon skipping of Fas pre-mRNA was regulated by RBM10,
while those of caspase 2, 3 and 9 were not. These results in the
same stage (i.e., exon skipping) of splicing must have arisen from
pre-mRNPs with different protein constituents, and spliceosomes
with different splicing regulators such as RBM10. Spliceosome
heterogeneity will become an important issue in understanding
the action mechanisms of individual regulators.
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Appendix A
We were almost ﬁnished preparing this manuscript, when the
paper by Wang et al. was published in the September issue of
EMBO Molecular Medicine 5, 1431-442, 2013 [28].
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Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2014.01.
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